Tarsus Pharmaceuticals, INC Form 4 insider transactions

Katherine Goodrich, a Director at Tarsus Pharmaceuticals, Inc., received a stock option grant and Restricted Stock Units (RSUs) on June 25, 2026.

Andrew D. Goldberg, a Director at Tarsus Pharmaceuticals, Inc., received stock options and restricted stock units on June 25, 2026.

Tarsus Pharmaceuticals, Inc. reports that Director Scott W. Morrison was granted stock options and restricted stock units on June 25, 2026.

Director Wendy L. Yarno of Tarsus Pharmaceuticals, Inc. reported the acquisition of stock options and restricted stock units on June 25, 2026.

David E. Pyott, a Director at Tarsus Pharmaceuticals, received stock options and restricted stock units on June 25, 2026.

William J. Link, Ph.D., a director at Tarsus Pharmaceuticals, received stock options and restricted stock units as compensation for his services.

Jeffrey Farrow, CFO and CSO of Tarsus Pharmaceuticals, reported transactions involving common stock and restricted stock units.

Director Katherine Goodrich reported a sale of 2,954 shares of Tarsus Pharmaceuticals, Inc. common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

Director William J. Link, Ph.D. of Tarsus Pharmaceuticals, Inc. reported the sale of common stock under a pre-arranged trading plan.

Director Scott Morrison of Tarsus Pharmaceuticals, Inc. (TARS) reported transactions involving the acquisition of common stock through the settlement of Restricted Stock Units.

Director William J. Link acquired 2,954 shares of Tarsus Pharmaceuticals common stock through the settlement of vested Restricted Stock Units.

Andrew D. Goldberg, a Director at Tarsus Pharmaceuticals, Inc., reported a transaction involving the acquisition of common stock through the settlement of vested Restricted Stock Units.

Director David E.I. Pyott acquired 1,383 shares of Tarsus Pharmaceuticals common stock through the settlement of vested Restricted Stock Units.

Tarsus Pharmaceuticals' Chief Operating Officer, Seshadri Neervannan, sold 2,989 shares of common stock for $66.75 per share as part of a pre-arranged 10b5-1 trading plan.

Tarsus Pharmaceuticals' Chief Human Resources Officer, Dianne C. Whitfield, sold shares to cover tax withholding obligations from RSU vesting.

Tarsus Pharmaceuticals' General Counsel, Bryan Wahl, sold common stock to cover tax withholding obligations from RSU vesting.

Tarsus Pharmaceuticals' Chief Operating Officer, Seshadri Neervannan, sold shares to cover tax withholding obligations related to RSU vesting.

Tarsus Pharmaceuticals' Chief Commercial Officer, Aziz Mottiwala, sold 13,056 shares of common stock over three days to cover tax withholding obligations related to RSU vesting.

Tarsus Pharmaceuticals' Chief Medical Officer, Elizabeth Yeu Lin, sold shares totaling 1,144 common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Tarsus Pharmaceuticals' CFO, Jeffrey S. Farrow, sold common stock to cover tax withholding obligations from RSU vesting, not as a discretionary transaction.

Tarsus Pharmaceuticals CEO Bobak R. Azamian sold shares to cover tax withholding obligations related to RSU vesting, not a discretionary sale.

William J. Link, a director at Tarsus Pharmaceuticals, sold 12,500 shares of common stock on March 16, 2026, through a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals' Chief Human Resources Officer, Dianne C. Whitfield, acquired 23,909 shares of common stock through the vesting of Restricted Stock Units.

Tarsus Pharmaceuticals' General Counsel, Bryan Wahl, acquired 24,236 shares of common stock through the settlement of vested Restricted Stock Units and an Employee Stock Purchase Plan.

Jeffrey S. Farrow, CFO and CSO of Tarsus Pharmaceuticals, settled 13,042 vested Restricted Stock Units, acquiring common stock on March 15, 2026.

Tarsus Pharmaceuticals CEO Bobak R. Azamian reported the settlement of vested Restricted Stock Units and updated his beneficial ownership of company common stock.

Tarsus Pharmaceuticals' Chief Medical Officer, Elizabeth Yeu Lin, acquired 2,511 shares of common stock through the settlement of vested Restricted Stock Units.

Tarsus Pharmaceuticals' Chief Operating Officer, Neervannan Seshadri, sold 8,366 shares of common stock for $76.67 per share under a pre-arranged 10b5-1 trading plan.

Tarsus Pharmaceuticals Director Katherine Goodrich converted 2,233 Restricted Stock Units into common stock on December 15, 2025.

Tarsus Pharmaceuticals' Chief Human Resources Officer, Dianne C. Whitfield, sold common stock totaling 15,565 shares on January 2, 2026, through a pre-arranged 10b5-1 trading plan.